KR101455589B1 - Ｍａｇｅ-ａ3-마커의 특이적 검출을 위한 프라이머 및 프로브를 포함하는 암의 검출 및 진단을 위한 방법 - Google Patents

Ｍａｇｅ-ａ3-마커의 특이적 검출을 위한 프라이머 및 프로브를 포함하는 암의 검출 및 진단을 위한 방법 Download PDF

Info

Publication number
KR101455589B1
KR101455589B1 KR1020097001326A KR20097001326A KR101455589B1 KR 101455589 B1 KR101455589 B1 KR 101455589B1 KR 1020097001326 A KR1020097001326 A KR 1020097001326A KR 20097001326 A KR20097001326 A KR 20097001326A KR 101455589 B1 KR101455589 B1 KR 101455589B1
Authority
KR
South Korea
Prior art keywords
mage
seq
primer
sequence
probe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097001326A
Other languages
English (en)
Korean (ko)
Other versions
KR20090034900A (ko
Inventor
티에리 코체
올리비어 그루셀레
가브리엘레 안네-마리 비어
데니스 살롱가
크레이그 로렌스 스티븐스
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20090034900A publication Critical patent/KR20090034900A/ko
Application granted granted Critical
Publication of KR101455589B1 publication Critical patent/KR101455589B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020097001326A 2006-06-21 2007-06-21 Ｍａｇｅ-ａ3-마커의 특이적 검출을 위한 프라이머 및 프로브를 포함하는 암의 검출 및 진단을 위한 방법 Expired - Fee Related KR101455589B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
GB0612342.6 2006-06-21
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (2)

Publication Number Publication Date
KR20090034900A KR20090034900A (ko) 2009-04-08
KR101455589B1 true KR101455589B1 (ko) 2014-10-28

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097001326A Expired - Fee Related KR101455589B1 (ko) 2006-06-21 2007-06-21 Ｍａｇｅ-ａ3-마커의 특이적 검출을 위한 프라이머 및 프로브를 포함하는 암의 검출 및 진단을 위한 방법

Country Status (27)

Country Link
US (1) US8936919B2 (cg-RX-API-DMAC7.html)
EP (1) EP2041308B1 (cg-RX-API-DMAC7.html)
JP (2) JP2009540812A (cg-RX-API-DMAC7.html)
KR (1) KR101455589B1 (cg-RX-API-DMAC7.html)
CN (1) CN101506383B (cg-RX-API-DMAC7.html)
AU (1) AU2007263019B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0713599A2 (cg-RX-API-DMAC7.html)
CA (1) CA2656909A1 (cg-RX-API-DMAC7.html)
CO (1) CO6140072A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113290T1 (cg-RX-API-DMAC7.html)
DK (1) DK2041308T3 (cg-RX-API-DMAC7.html)
EA (1) EA016347B1 (cg-RX-API-DMAC7.html)
ES (1) ES2389513T3 (cg-RX-API-DMAC7.html)
GB (1) GB0612342D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20120761T1 (cg-RX-API-DMAC7.html)
IL (1) IL195975A (cg-RX-API-DMAC7.html)
MA (1) MA30565B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008016493A (cg-RX-API-DMAC7.html)
MY (1) MY147511A (cg-RX-API-DMAC7.html)
NO (1) NO20085290L (cg-RX-API-DMAC7.html)
NZ (1) NZ573809A (cg-RX-API-DMAC7.html)
PL (1) PL2041308T3 (cg-RX-API-DMAC7.html)
PT (1) PT2041308E (cg-RX-API-DMAC7.html)
SI (1) SI2041308T1 (cg-RX-API-DMAC7.html)
UA (1) UA95956C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007147876A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810695B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596545A (en) 2007-09-17 2013-05-31 Glaxosmithkline Biolog Sa Improved detection of mage-a expression
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572105B1 (en) * 2002-11-14 2011-08-31 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
ATE209690T1 (de) * 1994-03-01 2001-12-15 Ludwig Inst Cancer Res Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
DE60234115D1 (de) * 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572105B1 (en) * 2002-11-14 2011-08-31 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Res. 61(14):5544-51 *
Immunol Rev. 188:22-32 *
Mol Cell Biol. 19(11):7327-35 *

Also Published As

Publication number Publication date
IL195975A (en) 2012-08-30
PL2041308T3 (pl) 2012-11-30
US8936919B2 (en) 2015-01-20
GB0612342D0 (en) 2006-08-02
ES2389513T3 (es) 2012-10-26
HRP20120761T1 (hr) 2012-10-31
CA2656909A1 (en) 2007-12-27
CY1113290T1 (el) 2016-04-13
HK1127627A1 (en) 2009-10-02
WO2007147876A2 (en) 2007-12-27
JP2009540812A (ja) 2009-11-26
MX2008016493A (es) 2009-05-21
EA200802356A1 (ru) 2009-06-30
JP2013046630A (ja) 2013-03-07
SI2041308T1 (sl) 2012-10-30
EP2041308B1 (en) 2012-07-11
DK2041308T3 (da) 2012-10-08
MA30565B1 (fr) 2009-07-01
ZA200810695B (en) 2014-03-26
US20120040341A1 (en) 2012-02-16
NZ573809A (en) 2011-12-22
JP5705191B2 (ja) 2015-04-22
BRPI0713599A2 (pt) 2012-11-06
AU2007263019B2 (en) 2012-11-08
UA95956C2 (uk) 2011-09-26
WO2007147876A3 (en) 2008-05-15
CO6140072A2 (es) 2010-03-19
CN101506383A (zh) 2009-08-12
CN101506383B (zh) 2013-08-28
AU2007263019A1 (en) 2007-12-27
KR20090034900A (ko) 2009-04-08
IL195975A0 (en) 2009-09-01
NO20085290L (no) 2009-01-19
EA016347B1 (ru) 2012-04-30
MY147511A (en) 2012-12-31
EP2041308A2 (en) 2009-04-01
PT2041308E (pt) 2012-10-09

Similar Documents

Publication Publication Date Title
US12168044B2 (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
EP1073734B1 (en) Tumor associated nucleic acids and uses therefor
JP2012520663A (ja) 遺伝子発現の改良された検出
KR20100085917A (ko) 개선된 ｍａｇｅ-ａ 발현 검출법
AU3007999A (en) Isolated nucleic acid molecule encoding cancer associated antigens, the antigens per se, and uses thereof
JP2003517274A (ja) 癌関連抗原およびその使用
US6911529B1 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
JP2008512120A (ja) 癌−精巣抗原
JP5705191B2 (ja) Ｍａｇｅ−ａ３マーカーの特異的検出のためのプライマーおよびプローブを含む癌の検出および診断の方法
CN103748238A (zh) 癌中prame基因表达的检测
EP0970206B1 (en) Lage-1 tumor associated nucleic acids
US7001999B1 (en) Tumor associated nucleic acids and uses therefor
WO1999058546A1 (en) Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
WO2001000874A2 (en) Cancer associated antigens and uses therefor
WO2001040271A9 (en) Cancer associated antigens and uses therefor
JP2003520604A (ja) 癌関連抗原をコードする単離された核酸分子、癌関連抗原そのものおよびそれらの使用
WO2000020586A2 (en) Renal cancer associated antigens and uses therefor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171023

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171023

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000